07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

Abiraterone acetate: Additional Phase I/II data

Additional data from the open-label, U.S. Phase I/II COU-AA-002 trial in 31 evaluable patients showed that 24 (77%) patients experienced a >30% decline in PSA, 22 (71%) had a decline of >50% and 8 (26%)...
08:00 , Feb 25, 2008 |  BC Week In Review  |  Clinical News

CB7630 abiraterone acetate: Additional Phase I data

Data from the open-label, U.S. Phase I COU-AA-002 trial in 30 evaluable patients showed that once-daily CB7630 reduced PSA levels in 27 patients (90%); 16 (53%) had a >50% PSA decline. In 11 ketoconazole-naïve patients,...